cannapatientcare.com march/april 2022
|
cannabis patient care
9
data focus
Joint Pain
Patients who selected joint pain as their primar y symp-
tom equaled 1503 sessions. Of those sessions, 32.5 repor ted
using THC, 16.67 repor ted THCA, 8.62 repor ted CBD, 3.99 re-
por ted THCV, 2.84 repor ted CBDA, and 0.06 repor ted CBDV in
their product.
PRODUCT TYPE FOR PATIENTS REPORTING JOINT PAIN
CONSUMPTION
6.4%
Bong
5.6%
Other
71.9%
*Included
1.8%
Resin
20.9%
Flower
0.7%
Shatter
2.7%
Other
0.1%
Kief
1.9%
Wax
0.1%
Hash
CONSUMPTION METHOD FOR PATIENTS REPORTING JOINT PAIN
84.3%
Inhaling
13.7%
Orally
2%
Topical
*Included means the patient did not report a specific product type
SPECIFIC CONSUMPTION METHOD FOR PATIENTS
REPORTING JOINT PAIN
CONSUMPTION
51.3%
*Included
6.4%
Pipe
13.7%
Vap Pen
4.7%
Gummy
7.9%
Joint
3.2%
Other
7.7%
Bong
2.5%
Vaporizer
0.9%
Tincture
1.8%
Others
OVERALL RATING FOR PATIENTS REPORTING JOINT PAIN
33.6%
Score of 5
2.1%
Score of 1
33.9%
Score of 4
13.9%
Score of 0
13.2%
Score of 3
3.2%
Score of 2
*Included means the patient did not report a specific consumption method
